RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, José Jimenez et al.|Annals of Oncology|2018Cited by 424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Cristina Cruz et al.|EMBO Molecular Medicine|2018Cited by 271
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug responseDimitra Georgopoulou, Shelley Harris, Maurizio Callari et al.|Nature Communications|2021Cited by 59
Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1-</i> Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin SensitivityJorge Gómez‐Miragaya, Eva González‐Suárez, Ander Díaz‐Navarro et al.|Cancer Research|2019Cited by 19
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Cancer Research|2024Cited by 7